English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Significance Emerging cancer nanotechnology enables targeted delivery of substantial payloads of drugs to cancer sites with concomitant reduction of side effects due to the lesser accumulation in the critical organs. This prompts loading of nanocarriers with therapeutic cargo and contrast agents, allowing combined cancer therapy and tumor visualization, respectively. This paper reports the realization of such combined therapy using conjugates of radionuclide yttrium-90–doped upconversion nanoparticles and targeted toxin. The resultant hybrid complex showed high therapeutic efficacy and high imaging contrast both in vitro and in vivo.

Radioactive ( 90 Y) upconversion nanoparticles conjugated with recombinant targeted toxin for synergistic nanotheranostics of cancer

Radioactive ( ⁹⁰ Y) upconversion nanoparticles conjugated with recombinant targeted toxin for synergistic nanotheranostics of cancer